Quick Facts: Therapeutic Uses

• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): A treatment option used in adults to address inflammation in the nose and sinuses that is associated with nasal polyps.
• Chronic Rhinosinusitis without Nasal Polyps (CRSsNP): Indicated for use in adults for the management of chronic rhinosinusitis symptoms, even when nasal polyps are not present.

---

Xhance is a prescription medication used to manage and address chronic inflammatory conditions within the nasal passages and sinuses in adults. Its authorized uses include the treatment of two specific clinical presentations of long-term rhinosinusitis.

One primary use is the management of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). This treatment is considered for adults experiencing persistent inflammation and the presence of nasal polyps.

The medication is also indicated for the management of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in adults. This application focuses on providing symptom relief and addressing inflammation in patients who have chronic rhinosinusitis but do not exhibit nasal polyps.

Xhance is indicated for these uses in adult patients. Healthcare professionals determine if this treatment is appropriate based on an individual's specific diagnosis and clinical needs. The goal of treatment is to support symptom management associated with these chronic conditions.

Xhance is authorized only for use in adults (aged 18 and older) for its approved indications. Safety and effectiveness are not established in pediatric patients (children and adolescents younger than 18 years of age).

---

Contraindications

The medicine must not be used by any patient with a known hypersensitivity (allergy) to fluticasone propionate or any other ingredient in Xhance.

---

Eligibility-Related Restrictions

Official regulatory labeling imposes restrictions and cautions for several populations:

• Nasal Integrity: Use should be avoided in patients who have recently had nasal surgery, nasal trauma, or nasal ulcerations until complete healing has occurred.
• Infections: Caution is required for patients with certain existing infections, including tuberculosis, systemic fungal/bacterial/viral/parasitic infections, or ocular herpes simplex.
• Systemic Conditions: Close monitoring is warranted for individuals with a history of glaucoma or cataracts, as well as for patients with hepatic impairment (liver problems).
• Pregnancy/Lactation: Use during pregnancy is advised only if the potential benefit outweighs the potential risk. It is not known if the medicine passes into human milk during lactation.

The official interaction profile for Xhance (Fluticasone Propionate) focuses on how other substances may affect its concentration in the body.

Interaction Scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions	Strong Cytochrome P450 3A4 (CYP3A4) inhibitors
Specific interacting medicines (if explicitly listed)	Ritonavir, Ketoconazole (as examples of strong CYP3A4 inhibitors)
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic interaction; Fluticasone Propionate is a CYP3A4 substrate and is metabolized by this enzyme.
Timing-based interaction rules (if applicable)	None explicitly documented as mandatory timing separation rules in the regulatory label.
Population-specific interaction notes (if applicable)	Severe Hepatic Impairment requires monitoring for increased drug exposure due to potential for reduced clearance.

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification	Clinically significant when co-administered with strong CYP3A4 inhibitors, as this increases systemic exposure.
Interaction-context constraints	Co-administration with the strong inhibitor Ketoconazole increased Fluticasone Propionate exposure approximately 1.9-fold.

Resulting Interaction Structure

The use of Xhance with the potent CYP3A4 inhibitor ritonavir is not recommended due to the potential for a significant increase in systemic exposure. Additionally, co-administration with other corticosteroids (including systemic, inhaled, or other nasal products) may cause a pharmacodynamic interaction leading to additive systemic corticosteroid effects. Grapefruit juice, which acts as a CYP3A4 inhibitor, may also increase systemic exposure. Regulatory documents require monitoring for patients with severe liver disease due to potentially reduced drug clearance.

Regulating Inflammation at the Genomic Level

The drug initiates its effect by acting as a high-affinity agonist for the intracellular Glucocorticoid Receptor (GR). This binding leads to genomic modulation, where the molecule complex enters the cell nucleus to perform transrepression—inhibiting genes that produce pro-inflammatory signaling molecules like cytokines—and simultaneously enhancing genes that produce anti-inflammatory proteins. This direct control over gene expression limits the expression of pro-inflammatory genes and the recruitment of inflammatory cells such as eosinophils.

---

Limiting Fluid Leakage and Mucosal Edema

A consequence of this anti-inflammatory cascade is the effect on local fluid dynamics. The drug causes localized vasoconstriction (narrowing of blood vessels) and reduces vascular permeability, which limits the leakage of fluid and proteins from the blood vessels into the mucosal tissue. This physiological change prevents the accumulation of fluid volume, contributing to the resolution of mucosal edema.

---

Delivery to Target Sinonasal Anatomy

The Exhalation Delivery System (EDS) provides a physical mechanism to deliver the drug to the target tissue. By utilizing the patient's exhaled breath, the system propels the medication to the narrow clefts and openings (ostia) that lead to the paranasal sinuses. This delivery method ensures the localized molecular mechanism is physically applied to the deeper, anatomically constrained areas of the sinonasal anatomy.

The use of Xhance is defined by its delivery via the topical intranasal route using a specialized Exhalation Delivery System (EDS) device. This system is engineered to utilize the patient’s exhaled breath to help distribute the fluticasone propionate suspension into the deeper regions of the nasal passages and sinuses.

The standard administration regimen for adults (18 years and older) is one spray per nostril, twice daily, delivering a total daily dose of 372 mcg. The dosage can be adjusted up to the maximum approved regimen of two sprays per nostril, twice daily, corresponding to a total daily dose of 744 mcg. All doses must be taken at regular intervals.

Correct procedural steps are necessary to ensure proper drug delivery. The device must be shaken before each use. It requires priming (seven sprays) when new and re-priming (two sprays) if it has remained unused for seven or more days. The delivery technique involves placing the mouthpiece in the mouth and the nosepiece in the nostril, then exhaling forcefully through the mouthpiece while simultaneously activating the spray pump. If a dose is missed, the patient should not double the dose and must take the next dose at the regular scheduled time. Consistent and regular use is a key principle, as the medication’s full effect may require several months of application.

Research Evidence / Overview of Studies for Xhance

---

Research Evidence for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Clinical research on Xhance for treating nasal polyps in adults has relied primarily on short-term Randomized Controlled Trials (RCTs). These are formal studies where participants receive either the medicine or a placebo (no medicine) for comparison. The studies included adults, some of whom had persistent symptoms despite prior use of standard nasal steroids and others who had previously undergone sinus surgery.

Researchers used a combination of objective and subjective metrics to understand the data collected during the research. Objective assessments focused on changes in the Bilateral Nasal Polyp Grade, a measurement of polyp size assessed by a clinician via endoscopy. Subjective assessments tracked patient-reported outcomes, most notably feelings of Nasal Congestion/Obstruction and overall sinonasal quality of life.

---

Research Evidence for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

For adults with chronic rhinosinusitis symptoms but without nasal polyps, the evidence also stems from Randomized Controlled Trials (RCTs), some lasting up to 24 weeks. Studies evaluated patient-reported experiences using a Composite Symptom Score, examining scores for issues like facial pain/pressure, nasal discharge, and congestion. Researchers also used objective, radiographic outcomes that tracked changes in Sinus Opacification Volume on CT scans, a measure of inflammation within the sinuses.

Long-Term Research and Durability of Follow-Up

The core evidence from the Randomized Controlled Trials for both conditions is generally limited to follow-up durations of 16 to 24 weeks. The controlled data covers short-term findings but leaves questions about the observed symptom patterns during extended observation. To gain further insight, researchers conduct intermediate- and long-term follow-up using prospective, uncontrolled, open-label extension studies.

What Remains Unclear or Uncertain About the Evidence

Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. Long-term effects are not fully established. The primary clinical trials have limited follow-up durations, and research highlights that the data for continuous use beyond six months or one year primarily comes from uncontrolled settings.

Key Studies & References

1. Full Prescribing Information for XHANCE (fluticasone propionate) Nasal Spray
2. Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2)

Common questions about Xhance (FAQ)

---

Q: How long does it typically take to start noticing a change with Xhance?

Like other nasal corticosteroids, Xhance doesn't have an immediate effect on symptoms. While some people experience initial improvement after several days of regular use, the greatest effect observed in clinical studies is described as requiring several months of consistent application, according to official product information.

Q: Can Xhance cause drowsiness or affect driving?

Dizziness is mentioned in official data as a less common side effect. However, official product information doesn't explicitly report drowsiness or direct limitations on driving ability among the documented adverse reactions.

Q: Are there any common over-the-counter medications that interact with Xhance?

Regulatory documents state that interactions are mainly focused on strong CYP3A4 inhibitors, which are a class of medications that can increase the amount of Xhance in the body. Official documents emphasize the importance of informing a healthcare provider about all medicines being taken, including over-the-counter products, as interactions may cause serious side effects.

Q: What common supplements or vitamins might interact with Xhance?

Official product information suggests informing a healthcare provider about all supplements, vitamins, and herbal products being used. This is because Xhance may interact with certain other substances, which could potentially cause side effects.

Q: Can Xhance be used long-term?

Official warnings state that patients using Xhance long-term require periodic examinations to check for possible changes to the nasal lining. Long-term use of this class of medicine is generally associated with a risk of ocular effects, such as glaucoma and cataracts.

Q: What is the expected duration of treatment with Xhance?

Official information states that the medicine should be used regularly as directed. Patients should not stop using Xhance unless instructed to do so by a healthcare professional.

Q: Can I use Xhance if I have a liver or kidney condition?

Caution is advised for patients with moderate to severe hepatic impairment (liver problems) because it may affect the body’s ability to process the medication. There is no specific requirement to adjust the dosage for people with renal impairment (kidney problems).

Q: How does Xhance differ from a regular nasal spray?

Xhance utilizes a specialized Exhalation Delivery System (EDS) to administer the medicine. This system is designed to use the patient’s exhaled breath to help propel the medicine deeper into the nasal cavity and the areas where the sinuses ventilate, which is a different mechanism than a traditional nasal spray.

Q: What happens if I forget to use Xhance one day?

According to the official patient counseling information, if a dose is missed, it should be skipped entirely. The patient is directed to take the next dose at the regular scheduled time and should not double the dose to make up for the missed one.

Q: Is it safe to use Xhance with alcohol?

Official drug interaction statements indicate that Xhance is not known to have a specific interaction with alcohol. As a general principle, it is recommended to discuss alcohol consumption with a healthcare provider.

Q: Is Xhance safe for older adults (seniors)?

Official information indicates that no noticeable variations in the safety and effectiveness of the drug were observed between patients aged 65 and older and younger adults during clinical studies.

Q: Does Xhance have a black box warning?

The official safety documents from regulatory authorities do not report a Black Box Warning for Xhance.

Q: Is Xhance used for simple allergies?

The approved indications for Xhance are for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in adults.

Q: Is Xhance safe for women who are pregnant or planning to be?

Official regulatory information states that use during pregnancy is considered only if the potential benefit to the patient outweighs the potential risk to the fetus, as described in official documents.

Q: Is Xhance safe for breastfeeding mothers?

It is not currently known if Xhance passes into human breast milk or if it can harm a nursing baby. Patients are advised to inform their healthcare provider if they are currently breastfeeding.

Q: Is there a generic version of Xhance available?

Xhance is the brand name for the generic medicine fluticasone propionate, delivered via a specialized system. While generic fluticasone propionate nasal sprays exist, the unique Exhalation Delivery System is specific to the Xhance product.

Q: Are there any dietary restrictions while using Xhance?

The regulatory information notes that consuming grapefruit or grapefruit juice may interact with the medicine, potentially increasing the drug’s level in the body. Beyond grapefruit, no other specific dietary restrictions are listed.

Q: Can children or teenagers use Xhance?

Xhance is indicated only for use in adults who are 18 years of age and older. The safety and effectiveness of the drug have not been established in pediatric patients (children and adolescents).

Q: Does Xhance affect your sense of smell?

A reduction in the sense of smell is a common symptom of the conditions Xhance is approved to treat. It is not listed as a common or serious side effect in the official adverse reaction lists.

Q: Are there specific instructions for cleaning the Xhance device?

The official documentation directs patients to follow the 'Instructions for Use' that come with the medicine. Patients should consult with their pharmacist or healthcare provider, who can show them how to correctly use, prime, and clean the device according to the full instructions.

Q: Does Xhance have any documented effects on mental health or mood?

Mental depression is listed in official adverse reaction data as a potential symptom of systemic corticosteroid effects, such as hypercorticism, that may occur with long-term use or overuse of the medicine.

Storage Conditions

Xhance must be stored at room temperature, specifically between 59 F and 77 F (15 C and 25 C). The medicine must be protected from freezing, extreme heat, cold, and light. It is required to keep the medicine in its original container with the cap on when not in use.

Child Safety and Stability

The product must be kept out of the reach of children. The device should be discarded after 120 sprays following the initial priming, even if some liquid remains in the bottle, to ensure the correct dose is delivered.

Disposal Instructions

Expired or unused Xhance should be disposed of by following a local drug take-back program. If a take-back program is not available, the medicine should be mixed with an undesirable substance, placed in a sealed bag or container, and then thrown in the household trash. Do not flush this medication down the toilet unless expressly advised by a regulatory authority.